The effect of sodium butyrate in combination with ATRA on the proliferation/differentiation of SKM-1

Abstract

To explore the molecular mechanisms of sodium butyrate working on SKM-1 cell proliferation/differentiation and to study its synergistic effect with all-trans retinoic acid (ATRA), SKM-1 cells were grown in the absence or presence of sodium butyrate and/or ATRA. The percentage of viable cells was determined by trypan blue exclusion. Differentiation was dtermined by nitroblue tetrazolium (NBT) reduction and cell surface adhesion molecules was analyzed by FACS. Cell cycle distribution was examined after DNA staining by propidium iodide. D-type cyclins, cdks and P21 mRNA were studied by reverse transcription-polymerase chain reaction. Our results showed that sodiun butyrate and/or ATRA blocked cells mainly in the G₀/G₁ phase of the cell cycle. ATRA inhibited the mRNA expression of CDK6, CDK4, cyclinD3 and cyclinD1. Sodium butyrate inhibited the mRNA expression of CDK2, cyclinD2 and cyclinD1. ATRA and sodium butyrate inhibited the mRNA expression of CDK6, CDK4, CDK2, cyclinD1, cyclinD2 and cyclinD3. Both ATRA and/or sodium butyrate stimulated p21 expression at the mRNA levels Our results suggest that the effect of sodium butyrate on cell proliferation/differentiation might be linked to its ability to induce expression of p21 mRNA and inhibit the cyclin-cdk complexes. Our observations support the notion that the sodium butyrate works synergistically with ATRA.

Keywords

sodium butyrate / ATRA / SKM-1 / cell cycle

References

[1] SilvermanL R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist, 2001, 6(Suppl 5): 8-8

[2] KizakiM, KoefflerH P. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol, 1992, 1995-95

[3] ButlerL M, AgusD B, ScherH I, et al. . Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cellsin vitro andin vivo. Cancer Res, 2000, 60(18): 5165-5165

[4] NakagawaT, MatozakiS, MurayamaT, et al. . Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol, 1993, 85(3): 469-469

[5] DuC, RednerR L, CookeM P, et al. . Overexpression of wild-type retinoic acid receptor a (RARa) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARa-fusion genes. Blood, 1999, 94793-793

[6] RednerR L, WangJ, LiuJ M. Chromatin remodelling and leukemia: new therapeutic paradigms. Blood, 1999, 94417-417

[7] XuL, GlassC K, RosenfeldM G. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet, 1999, 9140-140

[8] HodinR A, MengS, ArcherS, et al. . Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells. Cell Growth Differ, 1996, 7647-647

[9] HarperJ W, ElledgeS J, KeyomarsiK, et al. . Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell, 1995, 6387-387